NEWS & RESOURCES
CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB).
Metered CryosprayTM: a novel uniform, controlled, and consistent in vivo application of liquid nitrogen cryogenic spray.
CSA Medical Presents Positive Feasibility Study Results for its RejuvenAir® System at the 2019 European Respiratory Society International Congress
Results demonstrate a strong safety profile and clinically meaningful improvement in quality of life measures in chronic bronchitis patients at 12-month follow-up
RejuvenAir® recently achieved Breakthrough Device Designation by the U.S. FDA and will begin a U.S. Pivotal Study in 2020
CSA Medical said today that results of its feasibility study into the RejuvenAir metered cryospray system showed improved quality of life in patients who have chronic obstructive pulmonary disease with chronic bronchitis.